Does the media favor TRVI or ACRS?

In the previous week, Trevi Therapeutics and Trevi Therapeutics both had 2 articles in the media. Aclaris Therapeutics' average media sentiment score of 0.93 beat Trevi Therapeutics' score of 0.63 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TARS or ACRS?

In the previous week, Tarsus Pharmaceuticals had 5 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat Tarsus Pharmaceuticals' score of 0.79 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MBX or ACRS?

In the previous week, MBX Biosciences had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 3 mentions for MBX Biosciences and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat MBX Biosciences' score of 0.92 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABCL or ACRS?

In the previous week, AbCellera Biologics had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 3 mentions for AbCellera Biologics and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat AbCellera Biologics' score of 0.87 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NRIX or ACRS?

In the previous week, Nurix Therapeutics had 7 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 9 mentions for Nurix Therapeutics and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat Nurix Therapeutics' score of 0.60 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aclaris Therapeutics (ACRS) Competitors

$5.29 +0.27 (+5.38%)

Closing price 04:00 PM Eastern

Extended Trading

$5.68 +0.39 (+7.45%)

As of 07:59 PM Eastern

Compare

ACRS vs. TRVI, TARS, MBX, ABCL, and NRIX

Should you buy Aclaris Therapeutics stock or one of its competitors? MarketBeat compares Aclaris Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aclaris Therapeutics include Trevi Therapeutics (TRVI), Tarsus Pharmaceuticals (TARS), MBX Biosciences (MBX), AbCellera Biologics (ABCL), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry.

How does Aclaris Therapeutics compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Aclaris Therapeutics (NASDAQ:ACRS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Trevi Therapeutics has higher earnings, but lower revenue than Aclaris Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Aclaris Therapeutics	$7.83M	94.36	-$64.92M	-$0.56	N/A

In the previous week, Trevi Therapeutics and Trevi Therapeutics both had 2 articles in the media. Aclaris Therapeutics' average media sentiment score of 0.93 beat Trevi Therapeutics' score of 0.63 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trevi Therapeutics presently has a consensus price target of $22.90, suggesting a potential upside of 22.79%. Aclaris Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 117.39%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Trevi Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Trevi Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Trevi Therapeutics' return on equity of -24.53% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

Summary

Trevi Therapeutics beats Aclaris Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Aclaris Therapeutics (NASDAQ:ACRS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Aclaris Therapeutics has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.00	-$66.42M	-$1.14	N/A
Aclaris Therapeutics	$7.83M	94.36	-$64.92M	-$0.56	N/A

In the previous week, Tarsus Pharmaceuticals had 5 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat Tarsus Pharmaceuticals' score of 0.79 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tarsus Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Tarsus Pharmaceuticals presently has a consensus target price of $90.67, suggesting a potential upside of 44.05%. Aclaris Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 117.39%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tarsus Pharmaceuticals has a net margin of -9.02% compared to Aclaris Therapeutics' net margin of -832.58%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

Summary

Aclaris Therapeutics beats Tarsus Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Aclaris Therapeutics (NASDAQ:ACRS) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

MBX Biosciences has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

98.3% of Aclaris Therapeutics shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MBX Biosciences has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. MBX Biosciences' return on equity of -24.52% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

MBX Biosciences presently has a consensus target price of $60.22, suggesting a potential upside of 9.10%. Aclaris Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 117.39%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Aclaris Therapeutics has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Aclaris Therapeutics	$7.83M	94.36	-$64.92M	-$0.56	N/A

In the previous week, MBX Biosciences had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 3 mentions for MBX Biosciences and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat MBX Biosciences' score of 0.92 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aclaris Therapeutics beats MBX Biosciences on 11 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Aclaris Therapeutics (NASDAQ:ACRS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

AbCellera Biologics has a net margin of -181.75% compared to Aclaris Therapeutics' net margin of -832.58%. AbCellera Biologics' return on equity of -14.86% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

AbCellera Biologics currently has a consensus price target of $7.80, suggesting a potential downside of 0.54%. Aclaris Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 117.39%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aclaris Therapeutics has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	31.88	-$146.41M	-$0.48	N/A
Aclaris Therapeutics	$7.83M	94.36	-$64.92M	-$0.56	N/A

In the previous week, AbCellera Biologics had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 3 mentions for AbCellera Biologics and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat AbCellera Biologics' score of 0.87 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Summary

Aclaris Therapeutics beats AbCellera Biologics on 9 of the 17 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Aclaris Therapeutics (NASDAQ:ACRS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Nurix Therapeutics currently has a consensus target price of $32.20, suggesting a potential upside of 32.73%. Aclaris Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 117.39%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Nurix Therapeutics has a net margin of -411.37% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

In the previous week, Nurix Therapeutics had 7 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 9 mentions for Nurix Therapeutics and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat Nurix Therapeutics' score of 0.60 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclaris Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	29.87	-$264.46M	-$3.16	N/A
Aclaris Therapeutics	$7.83M	94.36	-$64.92M	-$0.56	N/A

98.3% of Aclaris Therapeutics shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nurix Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Summary

Aclaris Therapeutics beats Nurix Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Aclaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRS vs. The Competition

Export

Metric	Aclaris Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$701.11M	$3.08B	$7.07B	$12.45B
Dividend Yield	N/A	1.86%	2.66%	6.16%
P/E Ratio	-9.45	19.38	27.51	24.87
Price / Sales	94.36	350.27	540.69	102.84
Price / Cash	N/A	57.53	48.53	58.59
Price / Book	6.22	4.28	11.01	6.54
Net Income	-$64.92M	$64.45M	$3.57B	$336.70M
7 Day Performance	7.52%	3.18%	2.56%	3.31%
1 Month Performance	16.26%	3.80%	0.89%	1.68%
1 Year Performance	272.54%	34.43%	36.84%	31.96%

Aclaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRS Aclaris Therapeutics	3.1562 of 5 stars	$5.29 +5.4%	$11.50 +117.4%	+241.5%	$701.11M	$7.83M	N/A	100
TRVI Trevi Therapeutics	2.4485 of 5 stars	$18.63 +2.6%	$22.90 +22.9%	+231.5%	$2.65B	N/A	N/A	20
TARS Tarsus Pharmaceuticals	3.3663 of 5 stars	$61.26 -2.6%	$90.67 +48.0%	+51.8%	$2.64B	$451.36M	N/A	50	Analyst Upgrade
MBX MBX Biosciences	1.5029 of 5 stars	$53.85 +2.9%	$60.22 +11.8%	N/A	$2.56B	N/A	N/A	N/A
ABCL AbCellera Biologics	0.9617 of 5 stars	$8.12 +10.0%	$7.80 -3.9%	+124.9%	$2.48B	$75.13M	N/A	500	Options Volume Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRS) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. TRVI, TARS, MBX, ABCL, and NRIX

How does Aclaris Therapeutics compare to Trevi Therapeutics?

Summary

How does Aclaris Therapeutics compare to Tarsus Pharmaceuticals?

Summary

How does Aclaris Therapeutics compare to MBX Biosciences?

Summary

How does Aclaris Therapeutics compare to AbCellera Biologics?

Summary

How does Aclaris Therapeutics compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. TRVI, TARS, MBX, ABCL, and NRIX

How does Aclaris Therapeutics compare to Trevi Therapeutics?

Which has preferable valuation & earnings, TRVI or ACRS?

Does the media favor TRVI or ACRS?

Do analysts prefer TRVI or ACRS?

Which has more volatility & risk, TRVI or ACRS?

Do institutionals and insiders hold more shares of TRVI or ACRS?

Is TRVI or ACRS more profitable?

Summary

How does Aclaris Therapeutics compare to Tarsus Pharmaceuticals?

Which has stronger earnings and valuation, TARS or ACRS?

Does the media favor TARS or ACRS?

Which has more risk and volatility, TARS or ACRS?

Do analysts prefer TARS or ACRS?

Do insiders and institutionals hold more shares of TARS or ACRS?

Is TARS or ACRS more profitable?

Summary

How does Aclaris Therapeutics compare to MBX Biosciences?

Which has more volatility & risk, MBX or ACRS?

Do insiders and institutionals hold more shares of MBX or ACRS?

Is MBX or ACRS more profitable?

Do analysts rate MBX or ACRS?

Which has higher earnings & valuation, MBX or ACRS?

Does the media favor MBX or ACRS?

Summary

How does Aclaris Therapeutics compare to AbCellera Biologics?

Is ABCL or ACRS more profitable?

Do analysts rate ABCL or ACRS?

Do institutionals & insiders hold more shares of ABCL or ACRS?

Which has preferable valuation & earnings, ABCL or ACRS?

Does the media refer more to ABCL or ACRS?

Which has more risk and volatility, ABCL or ACRS?

Summary

How does Aclaris Therapeutics compare to Nurix Therapeutics?

Do analysts prefer NRIX or ACRS?

Is NRIX or ACRS more profitable?

Does the media favor NRIX or ACRS?

Which has stronger earnings & valuation, NRIX or ACRS?

Do institutionals and insiders hold more shares of NRIX or ACRS?

Which has more risk and volatility, NRIX or ACRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools